CCR2 and atherosclerosis: The rhythmic behavior of myeloid cells provides a timed treatment strategy for CCR2 neutralization with antagonist RS102895, which efficiently reduced atherosclerosis with a short-time administration at ZT17 without disturbing microvascular recruitment (27), supporting the concept that the time and site-specific leukocyte recruitment pattern provides us with a beneficial manner to regulate the leukocyte migration with time-tailored therapy.